SCHEMBL4325829

SCHEMBL4325829

CCOC(=O)c1ccc(Cc2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.73
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
LMNA P02545 4/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
ESR1 P03372 1/20 0.59
CA7 P43166 1/20 0.59
CA9 Q16790 1/20 0.59
ESR2 Q92731 1/20 0.59
CA14 Q9ULX7 1/20 0.59
MAPT P10636 2/20 0.58
NAMPT P43490 1/20 0.58
GAA P10253 2/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
MAOA P21397 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8722968 0.89 ALDH1A1 (0.60) SMN1; SMN2KMT2AMEN1LMNACA12
Benzene SCHEMBL27873122 0.87 CA1 (0.76) SMN1; SMN2KMT2AMEN1LMNACA12
SCHEMBL25340300 0.86 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1LMNACA12
SCHEMBL11408485 0.86 KMT2A (0.76) SMN1; SMN2KMT2AMEN1LMNACA12
SCHEMBL24629199 0.86 ESR1 (0.82) SMN1; SMN2KMT2AMEN1LMNACA12
Ethyl Benzoate SCHEMBL55674 0.85 LMNA (0.70) SMN1; SMN2KMT2AMEN1LMNACA12
Ethyl Benzoate SCHEMBL25388294 0.85 LMNA (0.70) SMN1; SMN2KMT2AMEN1LMNACA12
Ethyl Benzoate SCHEMBL2762273 0.85 LMNA (0.70) SMN1; SMN2KMT2AMEN1LMNACA12
SCHEMBL8726454 0.84 LMNA (0.83) SMN1; SMN2KMT2ALMNACA12CA1
SCHEMBL8726462 0.84 NAMPT (0.70) SMN1; SMN2KMT2AMEN1LMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367649-A1 PHOTOCATALYSTS, PREPARATION AND USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2025-12-04 US disclosed
US-20170210695-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND DOW AGROSCIENCES LLC 2017-07-27 US disclosed
CN-101312948-B Biaryl substituted heterocycle inhibitors of lTA4H for treating inflammation DECODE GENETICS EHF 2015-01-14 CN disclosed
EP-1926708-B1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2014-06-18 EP disclosed
EP-1926708-B1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2014-06-18 EP disclosed
US-8598359-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENETICS EHF (IS) 2013-12-03 US disclosed
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF (IS) 2009-06-25 US disclosed
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF (IS) 2009-06-25 US disclosed
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE GENETICS, EHF (IS) 2009-06-25 US disclosed
US-7402684-B2 Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation DECODE GENECTICS EHF. (IS) 2008-07-22 US disclosed
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-03-22 US disclosed
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION DECODE CHEMISTRY, INC. (US) 2007-03-22 US disclosed
CN-1036919-C Pyrazole condensed ring derivatives, method of manufacturing the same, and androgen inhibitor OTSUKA PHARMA CO LTD (JP) 1998-01-07 CN disclosed
US-5516777-A PROSTATE CANCER THERAPY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-05-14 US disclosed
US-5409928-A Prostate diseases, alopecia OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-04-25 US disclosed
CN-1089609-A Pyrazole-fused ring derivatives, its manufacture method and male hormone inhibitor OTSUKA PHARMA CO LTD (JP) 1994-07-20 CN disclosed
EP-0594149-A2 Condensed pyrazole derivatives, method of manufacturing the same, and androgen inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-04-27 EP disclosed
EP-0369762-B1 Pesticides ROUSSEL UCLAF (FR) 1993-12-29 EP disclosed
US-5202356-A Insecticides, miticides THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-13 US disclosed
EP-0369762-A1 Pesticides ROUSSEL-UCLAF (FR) 1990-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163462-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S SMN1; SMN2 4829/4885KMT2A 3243/4885MEN1 4613/4885
US-20070066820-A1 BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION LTA4H, LTB4R, LTC4S SMN1; SMN2 4829/4885KMT2A 3243/4885MEN1 4613/4885
US-20170210695-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND PAICS, NUDT21, TIAL1 SMN1; SMN2 2351/4885KMT2A 328/4885MEN1 60/4885
US-20250367649-A1 PHOTOCATALYSTS, PREPARATION AND USE THEREOF PPOX, AOX1, CYP3A7 SMN1; SMN2 4072/4885KMT2A 1036/4885MEN1 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.